Ratings by Dawson James
| Date | Company | Symbol | Type | Rating (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/7/2012 | Onyx Pharmaceuticals | ONXX | New Coverage | Market Outperform (N/A) |
76.70 | 96.20 | 25.42% | Details |
| 11/27/2012 | Galena Biopharma | GALE | New Coverage | Market Outperform (N/A) |
1.69 | 2.60 | 53.85% | Details |
| 11/27/2012 | Cytokinetics | CYTK | Downgrade | Market Outperform (N/A) |
0.67 | 1.18 | 76.12% | Details |
| 11/27/2012 | Affymax, Inc. | AFFY | New Coverage | Market Outperform (N/A) |
23.55 | 1.40 | -94.06% | Details |
| 11/27/2012 | Keryx Biopharmaceuticals | KERX | New Coverage | Market Outperform (N/A) |
2.89 | 8.03 | 177.85% | Details |
| 11/27/2012 | Agenus Inc. | AGEN | New Coverage | Market Outperform (N/A) |
3.65 | 4.12 | 12.88% | Details |
| 11/27/2012 | Rockwell Medical Technologies | RMTI | New Coverage | Market Outperform (N/A) |
7.25 | 3.96 | -45.38% | Details |
| 11/27/2012 | Sarepta Therapeutic | SRPT | New Coverage | Market Outperform (N/A) |
31.01 | 37.94 | 22.35% | Details |
| 11/27/2012 | Spectrum Pharmaceuticals | SPPI | New Coverage | Market Outperform (N/A) |
11.28 | 8.55 | -24.2% | Details |
| 11/27/2012 | Astex Pharmaceuticals | ASTX | New Coverage | Market Outperform (N/A) |
2.61 | 5.12 | 96.17% | Details |
| 11/27/2012 | Adventrx Pharmaceuticals | ANX | New Coverage | Market Outperform (N/A) |
0.63 | 0.73 | 15.87% | Details |
| 11/27/2012 | Celsion Corp | CLSN | New Coverage | Market Outperform (N/A) |
7.80 | 0.99 | -87.31% | Details |
| 11/27/2012 | Navidea Biopharmaceuticals | NAVB | New Coverage | Market Outperform (N/A) |
2.54 | 2.50 | -1.57% | Details |
| 2/27/2012 | Neurometrix Inc. | NURO | New Coverage | Market Outperform (N/A) |
0.78 | 1.94 | 148.72% | Details |
| 12/28/2011 | Synergetics USA | SURG | Downgrade | Market Perform (N/A) |
7.34 | 3.09 | -57.9% | Details |
| 9/16/2011 | Netflix | NFLX | Maintain | Market Underperform (N/A) |
Details | |||
| 8/11/2011 | Bohai Pharmaceuticals | BOPH | New Coverage | Market Outperform (N/A) |
0.90 | 0.64 | -28.89% | Details |
| 7/5/2011 | Netflix | NFLX | New Coverage | Market Underperform (N/A) |
267.99 | 226.18 | -15.6% | Details |
| 6/17/2011 | Pluristem Therapeutics | PSTI | New Coverage | Market Outperform (N/A) |
2.90 | 3.06 | 5.52% | Details |
| 4/19/2011 | Antares Pharma | AIS | Upgrade | Market Outperform (N/A) |
1.67 | 3.30 | 97.6% | Details |
| 3/23/2011 | Level 3 Communications | LVLT | New Coverage | Market Outperform (N/A) |
20.10 | 22.04 | 9.65% | Details |
| 2/1/2011 | Synergetics USA | SURG | New Coverage | Market Outperform (N/A) |
4.60 | 7.34 | 59.57% | Details |
| 12/14/2010 | Apricus Biosciences | APRI | New Coverage | Market Outperform (N/A) |
3.39 | 2.65 | -21.83% | Details |
| 10/18/2010 | Microfluidics International | MFLU | New Coverage | Market Outperform (N/A) |
0.81 | 1.35 | 66.67% | Details |
